7:30AM Chelsea Therapeutics announces FDA approval of CH-4051 Phase II Protocol (CHTP) 4.04 : Co announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency. Chelsea plans to initiate patient screening next month and initiating treatment in October.
Market Data 
Markets 
AI
